Surgalign Looks to Extend Runway for HOLO Platform

Surgalign reported 1Q22 orthopedic sales of $20.6 million, -11.5% compared to 1Q21.

COVID-related procedure volume headwinds hurt the company in January and February.

Surgalign CEO Terry Rich said, "Surgalign will be a substantially different company, beginning in earnest in 2023. While we anticipate growth in the spine device market, the...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us